ClinicalTrials.gg
Active, not recruitingNCT06271837Updated Sep 3, 2026

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

A Phase 2 interventional study of Trastuzumab deruxtecan and Bevacizumab in Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer), sponsored by AstraZeneca. Active, not recruiting at 29 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
31st of 58
127 · median 139
Started
2024
with 7 others
Phase 2
33 of 58
23 open now
Primary completion
2027-02
later than 17 of 44 live
Registered
30th of 58
by date
Lead sponsor
9 of 58
AstraZeneca

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 31st largest by enrollment, is one of 8 that started in 2024, is one of 33 in phase 2, reaches primary completion later than 17 of the 44 other live ones, and was the 30th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.

03

Conditions studied

  • Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age.
  • Locally advanced, unresectable, or solid tumors based on most recent imaging.
  • expression.
  • performance status of 0-1.
  • Must provide an adequate FFPE tumor sample to centrally determine HER2 status and other correlatives.
  • Has measurable target disease assessed by the investigator based on 1.1.
  • Adequate organ function and bone marrow within 14 days before enrollment.
  • use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed .
  • Provision of signed and dated written ICF prior to mandatory study-specific procedures, sampling, or analyses.
  • Evidence of status or negative serum pregnancy test for females of who are sexually active with a non-sterilized male partner.

Exclusion criteria

Exclusion Criteria:

  • Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the gastric body or gastroesophageal junction.
  • Has substance abuse or any other medical conditions that may interfere with the patient's participation in the clinical study or evaluation of the clinical study results.
  • A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and concentrated ascites reinfusion therapy.
  • History of another primary except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated.
  • Has unresolved toxicities from previous anti cancer therapy.
  • Has any spinal cord compression, , or clinically active .
  • Uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals, or active infection including tuberculosis.
  • Active primary immunodeficiency, known uncontrolled active infection, or active or C infection.
  • Protocol-defined inadequate cardiac function.
  • History of (non-infectious) ILD/pneumonitis that required , has current ILD/pneumonitis or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Has a concomitant medical condition that would increase the risk of toxicity in the opinion of the investigator.
  • Anti cancer chemotherapy without an adequate treatment prior to enrollment.
  • Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  • Known allergy or to study treatment or any of the product or other mAbs.
  • Involvement in the planning and/or conduct of the study.
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  • Previous enrollment in the present study. Concurrent enrollment in another therapeutic clinical study (excluding observational studies).
  • For females only: Currently pregnant or breast feeding, or who are planning to become pregnant.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Part 1

    HER2 IHC 3+ solid tumors (excluding breast and gastric cancer)

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2 Cohort A

    HER2 IHC 2+ solid tumors (excluding breast and gastric cancer)

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 2 Cohort B

    HER2 IHC 1+ gynecologic cancers

    Drug: Trastuzumab deruxtecan

  • Experimental
    Part 3

    HER2 IHC 3+ or 2+ cervical cancer

    Drug: Trastuzumab deruxtecan · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR)

    Confirmed ORR is the proportion of patients who have a confirmed complete response or confirmed partial response per RECIST 1.1.

    Time frame: An average of approximately 12 months

Secondary outcomes

  1. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until the date of documented progression (per RECIST 1.1) or death in the absence of disease progression.

    Time frame: An average of approximately 12 months

  2. Disease control rate (DCR)

    The DCR is defined as the percentage of patients who have a confirmed complete response (CR) or partial response (PR) or stable disease (SD) per RECIST 1.1.

    Time frame: An average of approximately 12 months

  3. Confirmed best objective response (BOR)

    BOR is a patient's best response during their participation in the study up until RECIST 1.1-defined progression or the last evaluable assessment in the absence of RECIST 1.1-defined progression.

    Time frame: An average of approximately 12 months

  4. Progression-free survival (PFS)

    PFS is defined as the time from the date of enrollment until the date of objective progressive disease (PD) per RECIST 1.1 or death.

    Time frame: An average of approximately 12 months

  5. Overall survival (OS)

    OS is defined as the time from the date of enrollment until death due to any cause.

    Time frame: An average of approximately 12 months

  6. Occurrence of adverse events (AEs) and serious adverse events (SAEs)

    The grading scales found in the revised NCI CTCAE v5.0 will be utilized for all events.

    Time frame: An average of approximately 12 months

  7. Pharmacokinetics (PK) of T-DXd

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd, total anti-HER2 antibody and MAAA-1181a.

    Time frame: An average of approximately 12 months

  8. Immunogenicity of T-DXd

    Incidence of anti-drug antibodies against T-DXd in serum at each time point.

    Time frame: An average of approximately 12 months

07

Study locations

29 sites
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Dongyang, 322100, China
  • Research Site
    Guangzhou, 510145, China
  • Research Site
    Guangzhou, 510630, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310016, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 230031, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Lishui, 323000, China
  • Research Site
    Nanchang, 330029, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200001, China
  • Research Site
    Shanghai, 200011, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110016, China
  • Research Site
    Taiyuan, 030001, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xuzhou, 221009, China
  • Research Site
    Yinchuan, 750004, China
  • Research Site
    Zhengzhou, 450002, China
  • Research Site
    Zhengzhou, 450008, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 35 months is close to that.

Counting every sponsor, half of 1,303 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Feb 22, 2024
StartActual
Feb 22, 2024
Primary completionEst.
Feb 10, 2027
CompletionEst.
Feb 10, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06271837
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Feb 22, 2024
Primary completion
Feb 10, 2027 (estimated)
Completion
Feb 10, 2027 (estimated)
Last update
Sep 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion